Valuation: IN8bio, Inc.

Market Cap 10.84M 9.52M 8.95M 8.18M 15.29M 1.04B 15.4M 107M 41.66M 530M 40.72M 39.83M 1.72B P/E 2026 *
-0.99x
P/E 2027 * -1.16x
Enterprise Value 10.84M 9.52M 8.95M 8.18M 15.29M 1.04B 15.4M 107M 41.66M 530M 40.72M 39.83M 1.72B EV / Sales 2026 *
-
EV / Sales 2027 * 9.8x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day-3.51%
1 week+8.91%
1 month-14.06%
3 months-24.66%
6 months-33.73%
Current year-52.99%
1 week 1.03
Extreme 1.03
1.16
1 month 0.96
Extreme 0.96
1.22
Current year 0.88
Extreme 0.88
2.73
1 year 0.88
Extreme 0.88
2.73
3 years 0.88
Extreme 0.88
74.4
5 years 0.88
Extreme 0.88
282.72
10 years 0.88
Extreme 0.88
309.57
Manager TitleAgeSince
Chief Executive Officer 50 2015-10-31
Chief Tech/Sci/R&D Officer 72 2018-10-31
Director of Finance/CFO 43 2021-02-07
Director TitleAgeSince
Director/Board Member 50 2015-10-31
Director/Board Member 68 2019-06-30
Director/Board Member 64 2021-08-03
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Don

Director

-724,637 7.3589%
5/9/26 Free

Chairman

22,000 0.2234%
5/9/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
-3.51%+8.91%-46.34%-97.02% 10.84M
+0.06%+6.49%+60.29%+111.13% 74.18B
-0.10%-3.82%+34.21%+74.94% 59.55B
-2.05%-3.46%-18.60%+352.20% 25.84B
-2.39%+2.74%+0.19%-5.91% 24.73B
-0.98%+1.07%+21.45%-10.04% 20.87B
+1.29%-2.49%+152.11%+333.06% 15.32B
-2.44%-0.09%+42.50%+164.11% 14.06B
-3.91%-4.91%-14.10%+779.68% 13.12B
-1.12%-3.04%+15.72%+234.56% 11.85B
Average -1.52%+0.53%+24.74%+193.67% 25.95B
Weighted average by Cap. -0.83%+0.70%+36.26%+161.33%

Financials

2026 *2027 *
Net sales - 1.11M 971K 913K 835K 1.56M 106M 1.57M 10.96M 4.25M 54.03M 4.15M 4.06M 175M
Net income -20.96M -18.4M -17.3M -15.81M -29.55M -2.01B -29.77M -208M -80.54M -1.02B -78.73M -77M -3.32B -23.72M -20.82M -19.57M -17.9M -33.44M -2.27B -33.69M -235M -91.15M -1.16B -89.09M -87.14M -3.76B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
26-09-23 US$1.100 -3.51% 22,606
26-09-22 US$1.140 +7.55% 41,926
26-09-21 US$1.060 -1.85% 13,775
26-09-18 US$1.080 +0.93% 20,305
26-09-17 US$1.070 +5.94% 48,055
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.100USD
Average target price
7.000USD
Spread / Average Target
+536.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock